Vaxcyte, Inc.
PCVX
$30.65
$1.535.25%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | 226.16% | 226.16% | 226.16% | 226.16% |
| Gross Profit | -- | -226.16% | -226.16% | -226.16% | -226.16% |
| SG&A Expenses | 53.05% | 48.52% | 47.74% | 48.69% | 52.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.69% | 68.76% | 90.17% | 93.52% | 101.52% |
| Operating Income | -21.69% | -68.76% | -90.17% | -93.52% | -101.52% |
| Income Before Tax | -15.33% | -69.49% | -87.78% | -78.32% | -80.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.33% | -69.49% | -87.78% | -78.32% | -80.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.33% | -69.49% | -87.78% | -78.32% | -80.00% |
| EBIT | -21.69% | -68.76% | -90.17% | -93.52% | -101.52% |
| EBITDA | -21.01% | -68.75% | -90.63% | -94.20% | -102.41% |
| EPS Basic | 6.81% | -37.84% | -39.23% | -23.41% | -19.88% |
| Normalized Basic EPS | 6.80% | -37.89% | -39.28% | -23.44% | -19.95% |
| EPS Diluted | 6.81% | -37.84% | -39.23% | -23.41% | -19.79% |
| Normalized Diluted EPS | 6.80% | -37.89% | -39.28% | -23.44% | -19.95% |
| Average Basic Shares Outstanding | 25.58% | 24.72% | 33.17% | 43.72% | 49.77% |
| Average Diluted Shares Outstanding | 25.58% | 24.72% | 33.17% | 43.72% | 49.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |